Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
03. März 2023 08:41 ET
|
Radiopharm Theranostics
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
03. März 2023 07:30 ET
|
Radiopharm Theranostics
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both...
Radiopharm Theranostics Initiates Process for Nasdaq Listing
14. Februar 2023 08:00 ET
|
Radiopharm Theranostics
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023 SYDNEY, Australia, Feb. 14, 2023 ...